Federal officials make the case for studying Tpoxx (tecovirimant) for monkeypox in randomized controlled trials in an opinion piece in the New England Journal of Medicine on 3 August, amidst clamor for the drug under expanded access and criticism of the hoops required to get the drug through that compassionate use process.
Authors of the NEJM piece, led by US Food and Drug Administration Office of Infectious Diseases Deputy Director Adam Sherwat,...






